Synaptogenix, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alan J. Tuchman MBA(FAAN)
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1185 Avenue of the Americas New York City NY United States of America 10036
- IPO Date
- Dec 8, 2020
- CIK
- 0001571934
- Website
- synaptogen.com
- Similar Companies
- Business
- Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases. Its core product platform is based on Bryostatin-1, a small molecule activator of protein kinase C (PKC) enzymes that promotes synaptogenesis, neural plasticity, and cognitive function. Bryostatin-1 is primarily targeted for the treatment of Alzheimer's disease, currently in Phase 2 clinical trials, and has received Orphan Drug Designation from the FDA for the treatment of Fragile X syndrome. The company is also exploring potential therapeutic applications of Bryostatin-1 and related compounds for other neurological conditions including multiple sclerosis, stroke, traumatic brain injury, and Niemann-Pick Type C disease, with preclinical and clinical studies ongoing. Synaptogenix's research efforts include development of polyunsaturated fatty acid (PUFA) analogs for spinal cord injury, with recent collaborative preclinical trials with LSU Health New Orleans. Founded in 2012 and headquartered in New York, New York, Synaptogenix has expanded its intellectual property portfolio through exclusive license agreements, such as with the University of California, Riverside. Recently in 2025, the company pivoted strategically by changing its corporate name to TAO Synergies Inc. and commenced trading under a new ticker symbol "TAOX" on Nasdaq, reflecting a notable shift towards a digital asset treasury strategy focused on cryptocurrency staking and AI innovation alongside its biopharmaceutical research. The company's latest operational updates include FDA clearance for a Phase 2b trial of Bryostatin-1 for advanced Alzheimer's disease and ongoing efforts to secure financing to support its clinical programs and new business directions. Synaptogenix is recognized for its rigorous clinical development pipeline, strategic partnerships, and a distinctive approach to addressing cognitive and neurodegenerative disorders through synaptic restoration therapies.
Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex
Tradr Expands Leveraged Lineup With 4 New Single-Stock ETFs Targeting AI Infrastructure Firms
Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys
Synaptogenix (TAOX) and The Competition Head-To-Head Survey
TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today
Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy
Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking
Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token
Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength
Synaptogenix Announces $5.0 Million Financing
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing
Synaptogenix President Daniel L. Alkon, M.D.
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
Best Penny Stocks To Buy Now? 7 Under $1 To Watch